Tadalafil

Generic Name
Tadalafil
Brand Names
Adcirca, Alyq, Cialis, Entadfi, Tadliq, Talmanco (previously Tadalafil Generics), Tadalafil Mylan, Tadalafil Lilly, Adcirca (previously Tadalafil Lilly)
Drug Type
Small Molecule
Chemical Formula
C22H19N3O4
CAS Number
171596-29-5
Unique Ingredient Identifier
742SXX0ICT
Background

Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy. It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like sildenafil, tadalafil has greater selectivity fo...

Indication

Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with finasteride for the treatment of benign prostatic hypertrophy (BPH). It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with macitentan or other endothelin-1 antagonists.

Associated Conditions
Benign Prostatic Hyperplasia (BPH), Erectile Dysfunction, Pulmonary Arterial Hypertension (PAH)
Associated Therapies
-
Clinical Trials
Related News
ir.unither.com
·

United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

United Therapeutics reports Q3 2024 revenue of $748.9M, up 23% YoY. CEO Martine Rothblatt highlights a $3B annual revenue run rate and upcoming clinical data reads. President Michael Benkowitz notes increasing demand for products serving pulmonary hypertension and high-risk neuroblastoma patients. Key financial highlights include net income of $309.1M and diluted EPS of $6.39.
defenseworld.net
·

American Century Companies Inc. Has $13.14 Million Position in United Therapeutics Co

American Century Companies Inc. increased its stake in United Therapeutics by 42.8% in Q2, owning 41,233 shares worth $13.135 million. Other investors also increased their holdings, with institutional investors owning 94.08% of the company's stock. CEO Martine A. Rothblatt sold 3,600 shares at $315.97 each, reducing her ownership to 130 shares valued at $41,076.10. CFO James Edgemond sold 7,802 shares at $345.41 each, leaving him with 3,210 shares worth $1.1 million. United Therapeutics reported $5.85 earnings per share for Q2, missing estimates by $0.48, with revenue up 19.8% YoY. Analysts predict $24.86 earnings per share for the current fiscal year. StockNews.com downgraded United Therapeutics from a "strong-buy" to a "buy" rating, while Morgan Stanley increased their price objective from $310.00 to $321.00.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy